SPOTLIGHT -
EP. 1: Prostate Cancer Management: Introduction and Overview
EP. 2: Managing ADT-Associated Skeletal-Related Events
EP. 3: Immunotherapy in Advanced Prostate Cancer, Part I
EP. 4: Immunotherapy in Advanced Prostate Cancer, Part II
EP. 5: NCCN Guidelines for Advanced Prostate Cancer
EP. 6: Treatments for Post-Docetaxel Prostate Cancer, Part I
EP. 7: Treatments for Post-Docetaxel Prostate Cancer, Part II
EP. 8: Emerging Therapies in Prostate Cancer
EP. 9: Dr. Shore Reviews Emerging Therapies in Prostate Cancer
EP. 10: Management of Patients with Advanced Prostate Cancer
EP. 11: Dr. Shore Discusses Therapy Combination in CRPC
EP. 12: Dr. Shore on the Management of Patients with CRPC
EP. 13: Reimbursement Issues in Prostate Cancer, Part I
EP. 14: Reimbursement Issues in Prostate Cancer, Part II
EP. 15: Revenue Opportunities and GPOs for Urology Groups
EP. 16: Effective Management of Prostate Cancer Conclusion
EP. 17: Dr. Shore on Current Clinical Trial Challenges in CRPC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
